Natera, INC Form 4 insider transactions

Natera Director Roy Baynes received 93 fully vested Restricted Stock Units as compensation for board service, increasing his beneficial ownership to 18,359 shares.

Natera's CEO and President, Steven Leonard Chapman, exercised stock options and subsequently sold a significant number of shares on November 3, 2025, under a pre-arranged trading plan.

Natera's Executive Chairman, Matthew Rabinowitz, reported the sale of 17,100 shares of common stock for approximately $3.42 million, executed under a pre-arranged 10b5-1 trading plan.

Natera's CEO, Steven Chapman, sold 6,015 shares of common stock across two transactions in late October 2025 to cover tax withholding obligations related to RSU vesting.

Natera's Chief Financial Officer, Michael Burkes Brophy, sold 5,063 shares of common stock across several transactions in late October 2025, primarily for tax withholding.

Natera Director and Co-Founder Jonathan Sheena sold shares of common stock to cover tax obligations related to RSU vesting, as per a pre-arranged 10b5-1 plan.

Natera's Secretary and Chief Legal Officer, Daniel Rabinowitz, sold shares of common stock to cover tax withholding obligations related to RSU vesting under a pre-arranged 10b5-1 plan.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold approximately $423,000 worth of common stock to satisfy tax obligations from RSU vesting.

Natera's President and Chief Business Officer, John Fesko, sold shares of common stock to cover tax obligations related to RSU vesting under a Rule 10b5-1 plan.

Natera's Chief Financial Officer, Michael Burkes Brophy, reported sales of common stock totaling 2,170 shares and the acquisition of 1,250 shares from RSU vesting in late October 2025.

Natera's Executive Chairman, Matthew Rabinowitz, sold 10,000 shares of common stock for $190 per share under a pre-arranged trading plan.

Natera Co-Founder Jonathan Sheena reported the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations, alongside existing direct and indirect holdings.

Natera's SEC and Chief Legal Officer, Daniel Rabinowitz, acquired common stock through RSU vesting and subsequently sold a portion to cover tax obligations.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 292 shares of common stock at $187.95 per share to cover tax obligations from RSU vesting.

Natera's President and Chief Business Officer, John Fesko, sold 339 shares of common stock to cover tax obligations related to RSU vesting.

Natera CEO Steven Chapman acquired shares from RSU vesting and sold a portion to cover tax obligations under a pre-arranged plan.

Natera's Chief Financial Officer, Michael Burkes Brophy, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Jonathan Sheena, Co-Founder and Director of Natera, Inc., reported the sale of 4,570 shares of common stock totaling approximately $807,235 through pre-arranged 10b5-1 trading plans.

Solomon Moshkevich, Natera's President of Clinical Diagnostics, sold 3,000 shares of common stock for approximately $480,000 pursuant to a pre-arranged trading plan.

Natera's SEC and Chief Legal Officer, Daniel Rabinowitz, reported the vesting of 2,500 restricted stock units and the subsequent sale of 1,364 shares for tax obligations.

Natera's CEO, Steven Leonard Chapman, reported the vesting of restricted stock units and subsequent sales of common stock under a pre-arranged trading plan.

Natera's Chief Financial Officer, Michael Burkes Brophy, acquired 6,250 shares through RSU vesting and subsequently sold 2,491 shares to cover tax withholding obligations.

Natera Co-Founder and Director Jonathan Sheena executed sales of 14,070 shares of common stock through pre-arranged 10b5-1 trading plans in September 2025.

Matthew Rabinowitz, Natera's Executive Chairman, reported sales of common stock totaling 49,990 shares across multiple transactions in September 2025, executed under Rule 10b5-1 trading plans.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, reported a charitable contribution of 300 shares of common stock.

Natera's Executive Chairman, Matthew Rabinowitz, sold 5,000 shares of common stock on September 12, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Steven Leonard Chapman, Natera's CEO and President, sold 5,079 shares of common stock on September 2, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 3,000 shares of common stock for approximately $500,000 through a pre-arranged 10b5-1 trading plan.

Natera Director Rowan E Chapman reported the acquisition of restricted stock units and the sale of common stock in recent transactions.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, acquired 1,675 shares through RSU vesting and subsequently sold 875 shares to cover tax obligations.